Clinical Trials Logo

Allergic Conjunctivitis clinical trials

View clinical trials related to Allergic Conjunctivitis.

Filter by:

NCT ID: NCT00375596 Withdrawn - Clinical trials for Allergic Conjunctivitis

A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis

Start date: n/a
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of a new allergy medication

NCT ID: NCT00364091 Completed - Clinical trials for Allergic Conjunctivitis

Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis

Start date: August 2006
Phase: Phase 3
Study type: Interventional

The purpose of this summary is to evaluate the efficacy and safety of R89674 0.025% ophthalmic solution compared with placebo or an active control in subjects with seasonal allergic conjunctivitis

NCT ID: NCT00331500 Completed - Clinical trials for Allergic Conjunctivitis

Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis

Start date: April 18, 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate that Olopatadine 0.2% is superior to vehicle in the treatment of the signs and symptoms associated with allergic conjunctivitis or rhinoconjunctivitis.

NCT ID: NCT00298337 Active, not recruiting - Asthma Clinical Trials

Use of Probiotic Bacteria in Prevention of Allergic Disease in Children 1999-2008

Start date: October 1999
Phase: Phase 2/Phase 3
Study type: Interventional

The aim of the study is to find out if allergic diseases can be prevented buy giving probiotic bacteria to pregnant mothers and their newborn infants

NCT ID: NCT00276445 Terminated - Clinical trials for Allergic Conjunctivitis

Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-Glucan

Start date: January 2004
Phase: Phase 4
Study type: Interventional

Intravenous- injection of beta-1,3-glucan in human is known to induce T helper type 1 response, while oral uptake did not. It was examined whether superfine dispersed beta-1,3-glucan (SDG) contrived to absorbed by intestinal mucosa would alleviate allergic symptoms by per-oral ingestion

NCT ID: NCT00244543 Completed - Clinical trials for Allergic Conjunctivitis

Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis

Start date: October 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to establish the efficacy of R89674 0.25% ophthalmic solution compared with placebo in alleviating the signs and symptoms of conjunctival allergen challenge-induced allergic conjunctivitis

NCT ID: NCT00241319 Completed - Clinical trials for Allergic Conjunctivitis

Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis

Start date: October 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to establish the efficacy of R89674 0.25% ophthalmic solution compared with placebo in alleviating the signs and symptoms of conjunctival allergen challenge-induced allergic conjunctivitis